Baltimore startup Vita Therapeutics raises $31M to advance treatment for genetic diseases
Baltimore's Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.
LEARN MORE